MedTrace Logo

Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity

NCT01530620 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2012-02-10

No results posted yet for this study

Summary

The purpose of this clinical study is to compare efficacy and safety of propiverine hydrochloride extended and immediate release formulations in patients suffering from neurogenic detrusor overactivity.

Conditions

  • Neurogenic Urinary Bladder Disorder
  • Urinary Bladder, Neurogenic
  • Bladder Disorder, Neurogenic
  • Urinary Bladder Disorder, Neurogenic
  • Neurogenic Bladder Disorder
  • Urinary Bladder Neurogenic Dysfunction
  • Urologic Diseases
  • Overactive Detrusor Function
  • Urinary Incontinence

Interventions

DRUG

Propiverine hydrochloride ER (extended release)

45 mg capsule (1x1/d)

DRUG

Propiverine hydrochloride IR (immediate release)

15 mg tablet (3x1/d)

Sponsors & Collaborators

  • APOGEPHA Arzneimittel GmbH

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2005-06-30
Completion
2006-07-31

Countries

  • Austria
  • Germany
  • Romania

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01530620 on ClinicalTrials.gov